Informations:
Erreur:
ID
17184
Description
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00401765
Lien
https://clinicaltrials.gov/show/NCT00401765
Mots-clés
Versions (1)
- 30/08/2016 30/08/2016 -
Téléchargé le
30 août 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Prostatic Neoplasms NCT00401765
Eligibility Prostatic Neoplasms NCT00401765
- StudyEvent: Eligibility
Similar models
Eligibility Prostatic Neoplasms NCT00401765
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
adenocarcinoma of the prostate
Item
histologically or cytologically confirmed adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
metastatic disease
Item
radiologically documented metastatic disease
boolean
C0027627 (UMLS CUI [1])
systemic chemotherapy for metastatic hormone refractory prostate cancer
Item
no prior systemic chemotherapy for metastatic hormone refractory prostate cancer
boolean
C1883256 (UMLS CUI [1,1])
C1328504 (UMLS CUI [1,2])
C1328504 (UMLS CUI [1,2])
progressive hormone-refractory disease
Item
progressive hormone-refractory disease after orchiectomy or gonadotropin-releasing hormone analog and/or anti-androgen treatment within 12 months of screening based on 1 of the following: transaxial imaging tumor progression, rise in 2 consecutive prostate-specifec antigen (psa) values obtained at least 7 days apart or radionucleotide bone scan progression
boolean
C1328504 (UMLS CUI [1])
C0677932 (UMLS CUI [2,1])
C0040405 (UMLS CUI [2,2])
C0201544 (UMLS CUI [3])
C0677932 (UMLS CUI [4,1])
C0203668 (UMLS CUI [4,2])
C0677932 (UMLS CUI [2,1])
C0040405 (UMLS CUI [2,2])
C0201544 (UMLS CUI [3])
C0677932 (UMLS CUI [4,1])
C0203668 (UMLS CUI [4,2])
karnofsky performance status
Item
karnofsky performance status of greater than or equal to 60
boolean
C0206065 (UMLS CUI [1])
psa
Item
prostate cancer that does not express serum psa or is less than 5.0 ng/ml at screening
boolean
C0201544 (UMLS CUI [1])
Investigational agent
Item
received any investigational drug/agent within 30 days or 5 half-lives, whichever is longer
boolean
C0013230 (UMLS CUI [1])
malignancy
Item
prior malignancy (other than prostate cancer) except adequately treated basal cell or squamous cell carcinoma of the skin or other cancer for which the subject has been disease-free for greater than or equal to 3 years
boolean
C0006826 (UMLS CUI [1])
central nervous system metastases
Item
known central nervous system metastases
boolean
C0686377 (UMLS CUI [1])
over-the-counter or herbal treatment for prostate cancer
Item
received any over-the-counter or herbal treatment for prostate cancer (eg, pc spes [an herbal refined powder]) within 4 weeks prior to screening.
boolean
C0013231 (UMLS CUI [1,1])
C0600139 (UMLS CUI [1,2])
C0242388 (UMLS CUI [2,1])
C0600139 (UMLS CUI [2,2])
C0600139 (UMLS CUI [1,2])
C0242388 (UMLS CUI [2,1])
C0600139 (UMLS CUI [2,2])